A Clinical Study to Evaluate SM17 for Atopic Dermatitis

Summary

This trial is a phase 2, randomized, double-Blind, placebo-Controlled, dose-finding clinical study conducted in participants with moderate-to-severe atopic dermatitis. The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics , and pharmacodynamics of SM17 (subcutaneous injection) in participants with moderate to severe atopic dermatitis.

Timeline

Start

2026-03-31

Primary completion

2027-04-25

Completion

2027-06-30

Drugs

Indications